ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026
Association between SGLT2 inhibitor use and the risk of vertebral augmentation after initial osteoporotic vertebral fracture in patients with type 2 diabetes.
Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSodium-glucose cotransporter-2 (SGLT2) inhibitors are widely used in patients with type 2 diabetes mellitus (T2DM), but their influence on post-fracture outcomes remains unclear. This study aimed to evaluate the association between SGLT2 inhibitor use and the risk of vertebral augmentation after an initial osteoporotic vertebral compression fracture (VCF) in patients with T2DM and osteoporosis.
methodsThis retrospective cohort study used data from the TriNetX Global Collaborative Network. Adults with T2DM, osteoporosis, and a first documented VCF were identified. Patients who received SGLT2 inhibitors within 6 months prior to the fracture were compared with non-users. Individuals with prior vertebral augmentation, vertebral malignancy, or inflammatory spondylopathies were excluded. Propensity score matching (1:1) was performed based on demographics, comorbidities, and concurrent medications. The primary outcome was vertebral augmentation within 6 months following the index fracture.
resultsAfter matching, 1757 patients were included in each cohort with well-balanced baseline characteristics. Within 6 months after the initial VCF, vertebral augmentation was performed in 12.5% of SGLT2 inhibitor users and 9.3% of non-users. SGLT2 inhibitor use was associated with a higher likelihood of vertebral augmentation (odds ratio 1.40; 95% confidence interval 1.13-1.73; p = 0.002).
conclusionIn patients with T2DM and osteoporosis, SGLT2 inhibitor use was associated with an increased likelihood of vertebral augmentation following an initial osteoporotic vertebral fracture, suggesting potential differences in post-fracture clinical course or management intensity.
Indexed as
Identifiers
41504956What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.